CEC INTL HOLD (00759) announced its interim performance with a net loss of 19.168 million Hong Kong dollars, a year-on-year decrease of 33.09%.
CEC INT'L HOLD (00759) announced its interim results for the six months ended October 31, 2025. The company reported a revenue of approximately 710 million Hong Kong dollars, representing a year-on-year increase of 1.14%. The net loss narrowed by 33.09% to 19.168 million Hong Kong dollars, with a loss per share of 2.88 Hong Kong cents.
CEC INT'L HOLD (00759) announced its interim results for the six months ending October 31, 2025, with a revenue of approximately HK$710 million, a year-on-year increase of 1.14%; a net loss of HK$19.168 million, a year-on-year narrowing of 33.09%; and a loss per share of 2.88 HK cents.
Related Articles
CHINA LESSO (02128) and Guangdong Liansu Electric have signed a parts supply agreement.
Jiangsu Hengrui Pharmaceuticals (01276): SHR-2906 Injection Obtains Drug Clinical Trial Approval Letter.
Jiangsu Hengrui Pharmaceuticals (01276): SHR-9539 injection, HRS-3738 tablets received the approval notice for drug clinical trials.
CHINA LESSO (02128) and Guangdong Liansu Electric have signed a parts supply agreement.
Jiangsu Hengrui Pharmaceuticals (01276): SHR-2906 Injection Obtains Drug Clinical Trial Approval Letter.
Jiangsu Hengrui Pharmaceuticals (01276): SHR-9539 injection, HRS-3738 tablets received the approval notice for drug clinical trials.
